Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Revenues Beat

Vertex (VRTX) PT Raised to $200 at Baird; Triple Update and Strong Results

Baird raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $186.00) while maintaining a Outperform rating.

Analyst Brian Skorney commented, "Vertex continues its momentum, releasing positive updates from its triple combination studies as well as impressive financial results and a solid... More

Vertex (VRTX) PT Raised to $183 at UBS

UBS raised its price target on Vertex (NASDAQ: VRTX) to $183.00 (from $174.00) while maintaining a Neutral rating.

Vertex (VRTX) PT Raised to $190 at Leerink Partners

Leerink Partners raised its price target on Vertex (NASDAQ: VRTX) to $190.00 (from $175.00) while maintaining a Outperform rating.

Vertex (VRTX) PT Raised to $212 at Piper Jaffray

Piper Jaffray raised its price target on Vertex (NASDAQ: VRTX) to $212.00 (from $205.00) while maintaining a Overweight rating.

Vertex Pharma (VRTX) Announces Selection of 2 Next-Generation Correctors, VX-659 & VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). The decision to advance VX-659 and VX-445 into Phase 3 development was based on initial Phase 2 data, including... More

Vertex (VRTX) PT Raised to $203 at Citi

Citi raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $200.00) while maintaining a Buy rating.

Vertex (VRTX) PT Raised to $193 at Deutsche Bank

Deutsche Bank raised its price target on Vertex (NASDAQ: VRTX) to $193.00 (from $175.00) while maintaining a Buy rating.

Vertex (VRTX) PT Raised to $200 at Barclays

Barclays raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $180.00) while maintaining a Overweight rating.